StreetInsider.com News Articles

Form SCHEDULE 13G Art Technology Acquisiti Filed by: ARISTEIA CAPITAL, L.L.C.

Thu, 14 May 2026 08:59:00 -0400

si-local-file:///var/storage/secattach/20260514/26490942.html

Form SCHEDULE 13G Art Technology Acquisiti Filed by: ARISTEIA CAPITAL, L.L.C.

Thu, 14 May 2026 08:59:00 -0400

si-local-file:///var/storage/secattach/20260514/26490942.html

Form 10-Q Art Technology Acquisiti For: Mar 31

Tue, 12 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260512/26478144.html

Form 10-Q Art Technology Acquisiti For: Mar 31

Tue, 12 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260512/26478144.html

Freedom Capital Markets Starts AtriCure (ATRC) at Buy

Wed, 01 Apr 2026 07:22:55 -0400

Freedom Capital Markets analyst Keith Hinton initiates coverage on Articure (NASDAQ: ARTC) with a Buy rating and a price target of $43.00.

The analyst comments "We initiate coverage of AtriCure (ATRC) with a BUY rating and 12-month $43 price target (~55% upside) based on ~19x 2027E EBITDA. Our bullish outlook is driven by five key assumptions: (1) the Afib franchise can continue to drive +LDD growth despite pending LAAM competition and MIS pressure; (2) CNB in pain can drive strong growth for the foreseeable future; (3) ATRC has two chances to triple the AtriClip TAM with reasonable chances for success; (4)

Freedom Capital Markets Starts AtriCure (ATRC) at Buy

Wed, 01 Apr 2026 07:22:55 -0400

Freedom Capital Markets analyst Keith Hinton initiates coverage on Articure (NASDAQ: ARTC) with a Buy rating and a price target of $43.00.

Freedom Capital Markets Starts AtriCure (ATRC) at Buy

Wed, 01 Apr 2026 07:22:55 -0400

Freedom Capital Markets analyst Keith Hinton initiates coverage on Articure (NASDAQ: ARTC) with a Buy rating and a price target of $43.00.

Freedom Capital Markets Starts AtriCure (ATRC) at Buy

Wed, 01 Apr 2026 07:22:55 -0400

Freedom Capital Markets analyst Keith Hinton initiates coverage on Articure (NASDAQ: ARTC) with a Buy rating and a price target of $43.00.

Form 10-K Art Technology Acquisiti For: Dec 31

Tue, 17 Mar 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260317/26176739.html

Form 10-K Art Technology Acquisiti For: Dec 31

Tue, 17 Mar 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260317/26176739.html

'2026 will be a stock-moving year for ArthroCare (ARTC)'; PT Lowered at Piper Sandler

Wed, 04 Mar 2026 07:52:56 -0400

Piper Sandler analyst Yasmeen Rahimi lowered the price target on ArthroCare (NASDAQ: ARTC) to $25.00 (from $72.00) while maintaining an Overweight rating.

The analyst commented: "Thoughtful Execution w/ 12-Week Ph2 CF Dosing To Begin 1H26; At 4Q/FY25 earnings, mgmt emphasized strong execution of both ARCT-032 cystic fibrosis (CF) and ARCT-810 ornithine transcarbamylase deficiency (OTCD) programs. Importantly, ARCT announced completion of 28-day Ph2 LunairCF Cohort 3 (n=4) where 15 mg ARCT-032 was generally safe and well-tolerated. Accordingly, the safety review committee gave the green-light to progress into a 12-week Ph2 study (up-to n=20 Class I CF; Cohort 4) which mgmt plans to

'2026 will be a stock-moving year for ArthroCare (ARTC)'; PT Lowered at Piper Sandler

Wed, 04 Mar 2026 07:52:56 -0400

Piper Sandler analyst Yasmeen Rahimi lowered the price target on ArthroCare (NASDAQ: ARTC) to $25.00 (from $72.00) while maintaining an Overweight rating.

Art Technology Acquisition prices $220 million IPO at $10 per unit

Mon, 05 Jan 2026 17:02:32 -0400

Art Technology Acquisition Corp. (NASDAQ: ARTCU) priced its initial public offering of 22 million units at $10.00 per unit, raising $220 million. The blank check company's units will begin trading on the Nasdaq Global Market on January 6, 2026.

Each unit consists of one Class A ordinary share and one-fourth of one redeemable warrant. The warrants are exercisable for Class A ordinary shares at $11.50 per share. Once the securities begin separate trading, the Class A shares and warrants are expected to trade under the symbols "ARTC" and "ARTCW," respectively.

The company was formed to pursue mergers, acquisitions or business combinations. Art

Art Technology Acquisition prices $220 million IPO at $10 per unit

Mon, 05 Jan 2026 17:02:32 -0400

The company was formed to pursue mergers, acquisitions or business combinations. Art

Art Technology Acquisition prices $220 million IPO at $10 per unit

Mon, 05 Jan 2026 17:02:32 -0400

The company was formed to pursue mergers, acquisitions or business combinations. Art

Art Technology Acquisition prices $220 million IPO at $10 per unit

Mon, 05 Jan 2026 17:02:32 -0400

The company was formed to pursue mergers, acquisitions or business combinations. Art

Art Technology Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

Mon, 05 Jan 2026 17:02:00 -0400

PHILADELPHIA, PA, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Art Technology Acquisition Corp. (NASDAQ:ARTCU) (the “Company”) today announced the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit. The Company’s units will be listed on the Nasdaq Global Market under the symbol “ARTCU” and will begin trading on January 6, 2026. Each unit issued in the offering consists of one Class A ordinary share of the Company and one-fourth of one redeemable warrant, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share. Once

Art Technology Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

Mon, 05 Jan 2026 17:02:00 -0400

Art Technology Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

Mon, 05 Jan 2026 17:02:00 -0400

Art Technology Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

Mon, 05 Jan 2026 17:02:00 -0400

AtriCure (ATRC) PT Raised to $45 at Needham

Wed, 30 Jul 2025 07:25:29 -0400

(Updated - July 30, 2025 7:25 AM EDT)

Needham analyst Mike Matson raised the price target on AtriCure (NASDAQ: ARTC) to $45.00 (from $44.00) while maintaining a Buy rating.

The analyst commented: "ATRC's 2Q25 revenue, EBITDA, and EPS beat consensus. For 2025, ATRC raised its revenue, adjusted EBITDA, and EPS guidance. Revenue growth improved to 17% in 2Q25 from 14% in 1Q25 driven by improved growth in Open-Ablation, Appendage Management, and Pain Management, as well as a smaller decline in Minimally Invasive Ablation. On a Y/Y basis, ATRC's gross margin was down 10 bps, while its operating margin was up 170 bps

AtriCure (ATRC) PT Raised to $45 at Needham

Wed, 30 Jul 2025 07:25:29 -0400

(Updated - July 30, 2025 7:25 AM EDT)

Needham analyst Mike Matson raised the price target on AtriCure (NASDAQ: ARTC) to $45.00 (from $44.00) while maintaining a Buy rating.

AtriCure (ATRC) PT Raised to $45 at Needham

Wed, 30 Jul 2025 07:25:29 -0400

(Updated - July 30, 2025 7:25 AM EDT)

Needham analyst Mike Matson raised the price target on AtriCure (NASDAQ: ARTC) to $45.00 (from $44.00) while maintaining a Buy rating.

AtriCure (ATRC) PT Raised to $45 at Needham

Wed, 30 Jul 2025 07:25:29 -0400

(Updated - July 30, 2025 7:25 AM EDT)

Needham analyst Mike Matson raised the price target on AtriCure (NASDAQ: ARTC) to $45.00 (from $44.00) while maintaining a Buy rating.

ArthroCare (ARTC) PT Raised to $53 at Canaccord Genuity

Wed, 30 Jul 2025 07:14:55 -0400

(Updated - July 30, 2025 7:14 AM EDT)

Canaccord Genuity analyst Kyle Rose raised the price target on ArthroCare (NASDAQ: ARTC) to $53.00 (from $51.00) while maintaining a Buy rating.

The analyst commented: "AtriCure reported a very solid Q2, with strength across the rest of the business more than offsetting further degradation of US EPi-Sense/ Hybrid. ATRC reported Q2 revenue of $136.1M (+16.5% Y/Y CC), ahead of CG’s $130.7M estimate and the consensus $130.2M. The company posted impressive profitability and cash generation numbers with $15.4M adjusted EBITDA, ahead of our $11.1M estimate and the consensus $10.0M, and AtriCure also generated cash flow